While oncogenic gene fusions involving transcription factors remain largely undruggable (Knott et al, 2019), clinical trials using larotrectinib, a kinase inhibitor targeting gene fusions involving NTRK1/2/3, have shown promising results and could offer a strategy for the treatment of NTRK‐fusion‐positive sarcomas (Doebele et al, 2015; Fig 3). The gene discussed is NTRK1; the disease is sarcoma.